1 / 35

And What’s Next?

And What’s Next?. Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA. Disclosures. Research Funding NCI Bristol Myers Squibb (to DFCI) Astra Zeneca (to DFCI) Consultant Bayer. What Have We Learned So Far?. Adjuvant therapy impacts outcome in stage III colon cancer

luigi
Télécharger la présentation

And What’s Next?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. And What’s Next? Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA

  2. Disclosures • Research Funding • NCI • Bristol Myers Squibb (to DFCI) • Astra Zeneca (to DFCI) • Consultant • Bayer

  3. What Have We Learned So Far? Adjuvant therapy impacts outcome in stage III colon cancer 5-FU and Oxaliplatin impact disease-free and overall survival Irinotecan, bevacizumab and cetuximab do not

  4. Four Groups of Stage III Colon Cancer Patients

  5. What Are the Challenges and Next Steps? Challenge 1 – Some people get chemotherapy who don’t need it Challenge 2 –Toxicity of therapy Challenge 3 – Not everyone is cured - what else can move the bar Challenge 4 – Other things “to do” outside of medications

  6. Challenges 1: Identifying Who Should Get Adjuvant Therapy in Stage III Colon Cancer Clinical features Molecular signatures NSABP C07 – O’Connell et al Abstract 3512 Oncotype Dx Colon 12 Interaction by oxaliplatin usage (P = 0.48)

  7. Challenge 2: Toxicities 5-FU toxicities Primarily all short term - with exception of DPD deficiencies, most patients easily managed Oxaliplatin toxicities Increased bone marrow suppression - short term – rare life threatening Liver toxicities - ? Long term effects NEUROPATHY

  8. Incidence of Neurosensory Symptoms during Treatment and Follow-up after FOLFOX Andre et al J Clin Oncol. 2009 Jul 1;27(19):3109-16.

  9. Oxaliplatin Toxicity Neuroprotectants Duration of therapy

  10. Intravenous Ca / Mg for Oxaliplatin-Induced Sensory Neurotoxicity: NCCTG N04C7 Grothey A et al. JCO 2011;29:421-427

  11. Intravenous Ca / Mg for Oxaliplatin-Induced Sensory Neurotoxicity: NCCTG N04C7 Time to grade 2 or worse sensory neuropathy as measured by (A) Common Toxicity Criteria for Adverse Events or by (B) an oxaliplatin-specific scale. Grothey A et al. JCO 2011;29:421-427

  12. Relapse-free Survival by Adjuvant Treatment Arms 6 Months of bolus 5FU/LV vs. 3 months of Continuous Infusion 5FU Chau I et al. Ann Onco 2005

  13. International Duration Evaluation of Adjuvant Chemotherapy (IDEA) group • Three or Six Colon Adjuvant Trial (TOSCA) • Activated June 2007. Goal 3,500 stage II/III colon • Short Course Oncology Treatment (SCOT) • Activated March 2008. Goal 9,500 stage II/III colon or rectal • GERCOR • Activated May 2009. Goal 2,000 stage III colon • HORG • Activated Oct 2010. Goal 1,000 stage II/III colon • CALGB/SWOG 80702 • Activated July 2010. Goal 2,500 stage III colon

  14. International Duration Evaluation of Adjuvant Chemotherapy (IDEA) group • All trials comparing 3 months FU/oxaliplatin versus 6 months FU/oxaliplatin (some include oral, most IV) • At least 10,500 stage III colon cancer patients pooled • DFS primary endpoint • Noninferiority if 2 sided 95% CI comparing 3 to 6 months lies entirely below 1.10

  15. Challenge 3: Not Everyone Is Cured What Else Can Move Bar? Moving from metastatic  adjuvant setting Approved but not been tested - Panitumumab Positive phase III data – Aflibercept, Regorafenib Cyclooxygenase inhibitors Associated with risk of colorectal cancer Prevent/reduce polyp # in patients with prior CRC or polyps Observational data associated with DFS

  16. CALGB 89803: Aspirin Use and Disease-Free Survival in Stage III Colon Cancer 1.00 Consistent aspirin users Non-consistent users 0.75 Log rank, p = 0.03 Proportion Disease-Free and Alive 0.50 HR = 0.46 (95% CI, 0.23-0.95) 0.25 0.00 0 10 20 30 40 50 Months Fuchs ASCO 2005 Abstract 3530

  17. Survival According to Aspirin Use After Diagnosis: Nurse’s Health Study Chan, A. T. et al. JAMA 2009;302:649-658.

  18. CALGB/SWOG 80702 for Stage III Colon Cancer Celecoxib versus Placebo N = 2,500 Arm A 12 FOLFOX + Placebo daily Arm B 12 FOLFOX + Celecoxib 400 mg daily 6 versus 12 treatments FOLFOX Arm C 6 FOLFOX + Placebo daily Arm D 6 FOLFOX + Celecoxib 400 mg daily Celecoxib starts concurrently with FOLFOX and continue for 3 years

  19. Challenge 4: Other things “to do” outside of medications Really extension of challenge 3 The questions many/most patients ask and we can’t answer (or can we?) What should I eat? Should I exercise? What about a multivitamin? What diet/lifestyle changes will help?

  20. Data from Observational Studies for Stage I-III Disease • Decrease risk of recurrence • Physical activity • Avoidance of Western pattern diet • Avoidance of class II/ III obesity (BMI > 35 kg/m2) • Aspirin or COX-2 inhibitor • Higher vitamin D levels • No association with recurrence to date • Weight change (gain or loss) • Obesity < 35 kg/m2 • Smoking status or history • Multivitamin Credits: Charles Fuchs Jeffrey Meyerhardt Brian Wolpin Kimmie Ng Andrew Chan Nadine McCleary Donna Niedzwiecki Donna Hollis CALGB

  21. 89803 and Exercise: Disease-Free Survivalin Stage III Colon Cancer Survivors Hazard Ratio Recurrence or Death Regular Physical Activity (met-hours per week) Meyerhardt, J. A. et al. J Clin Oncol; 24:3535-3541 2006

  22. Statistical Considerations • Reverse causality • Is the exposure changing outcomes or the outcome changing exposure • Restrict to events at least 90 days from exposure • Sensitivity analyses to extend restriction to 6 months and 12 months • Recall bias • The clock starts at time of questionnaire completion – all events are prospective beyond the exposure data • Limits generalizability – data speak to those that get to point of questionnaire

  23. 89803 and Exercise: Stratification Meyerhardt, J. A. et al. J Clin Oncol; 24:3535-3541 2006

  24. NHS and Post-diagnosis Physical Activity Meyerhardt, J. A. et al. J Clin Oncol; 24:3527-3534 2006

  25. NHS and Post-diagnosis Physical Activity Meyerhardt, J. A. et al. J Clin Oncol; 24:3527-3534 2006

  26. CHALLENGE: Colon Health and Life-Long Exercise Change trial High risk Stage II or stage III colon cancer - completed adjuvant chemotherapy within 2-6 months REGISTRATION Baseline Testing STRATIFICATION Disease stage high risk III; centre; BMI ≤ 27.5 vs. > 27.5; ECOG PS 0 vs. 1 RANDOMIZATION ARM 1 Physical Activity Program + General Good Health Education Material (Intervention Arm) ARM 2 General Health EducationMaterials (Control Arm) Assessment of disease-free survival every 6 months for first 3 years and annually from years 4-10 Courneya Curr Oncol.2008 Dec;15(6):271-8.

  27. NSABP and Body Mass Index Disease-free and overall survival by body mass index (BMI) category in 4288 patients from National Surgical Adjuvant Breast and Bowel Project randomized clinical trials for Dukes B and C colon cancer Dignam, J. J. et al. J. Natl. Cancer Inst. 2006 98:1647-1654

  28. Body Mass Index in Colon Cancer Patients over Past Decade

  29. 89803 and Change in Weight Ptrend = 0.13 Ptrend = 0.90 Meyerhardt J Clin Oncol. 2008 Sep 1;26(25):4109-15.

  30. CALGB 89803: DFS By Dietary Pattern 3.9 P, trend < 0.001 Western diet 2.2 2 1.2 1.1 1 1 1 0.7 4 3.5 3 2.5 2 Hazard Ratio for Cancer Recurrence or Death 1.5 1.3 1 Prudent diet 0.5 0 1 2 3 4 5 Quintiles of Dietary Pattern Meyerhardt, J. et al. JAMA 2007298(7):754-764.

  31. CALGB 89803: Dietary Pattern Meyerhardt, J. et al. JAMA 2007;298:2263-a.

  32. Plasma Vitamin D and Survival in Colorectal Cancer Patients: NHS/HPFS (N = 304) 1 1 0.9 0.89 0.83 0.8 P, trend = 0.01 0.7 0.6 Hazard Ratio for Death 0.5 0.49 0.4 (0.28-0.86) 0.3 People with highest level of vitamin D have 50% improvement in outcome 0.2 0.1 0 <22.8 22.8-27.1 27.2-33.1 >33.1 Quintiles of plasma Vitamin D ng/mL Ng et al J Clin Oncol. 2008 Jun 20;26(18):2984-91

  33. Predicted Vitamin D Level* & Survival in Colorectal Cancer Patients: NHS/HPFS (N=1017) CRC Specific Mortality Overall Mortality * Based on race, geography, exercise, BMI, dietary vitamin D, supplement vitamin D Ng et al Br J Cancer. 2009 101: 916-23.

  34. Conclusions Despite advances in adjuvant therapy in 80s, 90s and early 2000, bar has become stagnant We need to better define who needs therapy, who benefits and who needs other options Better understanding of complementary approaches will benefit our patients Potentially their colon cancer Other diseases down the road

More Related